Volume : 10, Issue : 05, May – 2023
Title:
73.NEWER THERAPEUTIC APPROACHES IN DIABETES-MELLITUS
Authors :
Saranya T.J , Soumya Surendran , Sneha Sanal , Abhijith Mohan , Lekshmi Krishna V.B , Savitha Mol G.M , Prasobh G.R
Abstract :
Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycaemia due to an absolute or relative deficit in insulin production or action. There are mainly two types of diabetes mellitus, Type 1 diabetes mellitus (insulin dependent diabetes mellitus -IDDM), Type 2 diabetes mellitus (non-insulin dependent diabetes mellitus). Controlling blood sugar through diet, oral medication for insulin is the main treatment. Regular screening for complications is also required. Oral hypogylcemic drugs are used for the treatment of diabetes mellitus and insulin is also used for its treatment in case of high glucose level. Nano formulations not only improve solubility of the drug but also provide several other benefits such as reduced dose, rapid onset of action, sustained drug release, fewer side effects, targeted drug delivery, enhanced half-life of the drug, reduced patient variability along with improved bioavailability and may thus overcome many of the limitations of the current anti-diabetics. Here in this review, we summarise diabetes mellitus and newer therapeutic approach in diabetes mellitus.
Keyword: Diabetes mellitus, Insulin,
Cite This Article:
Please cite this article in press Saranya T.J et al, Newer Therapeutic Approaches In Diabetes-Mellitus., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1: S81–S90.
2. Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK (eds). Robbins and Cotran Pathologic basis of disease (7th ed) 2005. Philadelphia, Saunders; 1156-1226.
3. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010; 36:628–651.
4. Arora, S., Ojha, S.K., Vohora, D., Characterisation of Streptozotocin induced diabetes mellitus in Swiss Albino mice, Glo J of Pharmacol., 3(2): 81-84 (2009)
5. Jothivel, N., Ponnusamy, S.P., Appachi, M., Antidiabetic activities of methanol leaf extract of Costus pictus D. Don in alloxan-induced diabetic rats, J of health sci.,53(6): 655-663 (2007).
6. Maria J. Meneses, Current Pharmaceutical Design, 2015, Vol. 21, No. 25,3608-3610
7. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997
8. Miriam Cnop, Nils Welsh and Decio L. Eizirik, Diabetics, Vol .54, supplement II 2005, S100-S101.
9. Sahil Singla, The Pharma Innovation Journal 2022; SP-11(6),1925-1927
10. Maria J. Meneses, Current Pharmaceutical Design, 2015, Vol. 21, No. 25,3608-3610
11. Sasikala P R, Meenal ks.in-silico molecular docking studies of multipotential compounds isolated from premna serratifolia L. Innovare Journal of Life science. 2016;4(3):1-8.
12. Cantuti-Castelvetri, L. Fitzner, D. Boch-Queralt, M. Wein, M.T. Su, M. Sen, Petan, Defective cholesterol clearance limits remyelination in the aged central nervous system. Science.2018;359:684-688.
13. Aline Augusti Boligon1, Med chem, an open access journal, Volume 4(7): 517-522 (2014) – 517.
14. Kavya Chitra mekala, Alain Gerald Bertoni, Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas, Volume 1; Page no; 49-58 ;2020.
15. Siddharth uppal, Kishal s. italia, Deepak chitkara, Acta Biomaterialia volume 201: page no 20-42.